Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
SANTA ANA, Calif., Aug. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.
The clear, viscous, low molecular weight dispersive OVD is intended for use as a surgical aid in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, and glaucoma filtration surgery.
Healon EndoCoat OVD's formula protects and coats the eye when injected during surgery, and is ideal for intraocular lens (IOL) lubrication and insertion. Additionally, Healon EndoCoat OVD can be used in combination with any other Healon products such as Healon OVD, Healon GV OVD or Healon5 OVD.
Dispersives such as Healon EndoCoat OVD are expected to account for 38 percent of the total OVD market in 2011, according to independent ophthalmic research firm Market Scope.
The Healon EndoCoat OVD delivery system includes a number of features for increased patient safety and ease of handling for the physician, including a smaller, 25-gauge cannula with guard and improved ergonomics of the device for a smooth and consistent delivery.
"Healon EndoCoat [OVD] plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety," said Donald Nixon, M.D., surgical director, TriMed Eye Center, Barrie, Ontario, Canada. "Additionally, the mechanical properties of Healon EndoCoat [OVD] provide me with the stability I need throughout the entire cataract procedure for even the most challenging cases."
Healon EndoCoat OVD is available in Europe, Canada and New Zealand and is currently under review by the U.S. Food and Drug Administration. Shipments to other geographies will follow once the company receives necessary regulatory approvals. Customers who already receive regular shipment